<DOC>
	<DOCNO>NCT01513603</DOCNO>
	<brief_summary>CLAG-M active , well tolerate regimen acute myelogenous leukemia . Each agent active Acute Lymphoblastic Leukemia ( ALL ) well . The current trial determine efficacy regimen patient relapse ALL .</brief_summary>
	<brief_title>Trial Cladribine , Cytarabine , Mitoxantrone , Filgrastim ( CLAG-M ) Relapsed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>Patients receive standard dose CLAG-M ( cladribine , cytarabine , mitoxantrone , filgrastim ) . Standard support care give . Efficacy assess bone marrow examination blood test .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Relapsed refractory acute lymphoblastic leukemia , Burkitts leukemia/lymphoma , Lymphoid blastic CML , Lymphoblastic lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>